Biotechnology company Relief Therapeutics has announced a business combination with commercial-stage company NeuroX to create a new digital neurotherapeutics company.  The business combination follows approval from Relief’s shareholders, who have also approved a capital increase through the issuance of 140 million new ordinary shares.   The business combination is expected to close in December 2025, subject to remaining closing conditions, including […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!